What Is Tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. With a molecular weight of approximately 4,813.45 Da and a biological half-life of roughly 5 days, it represents the most clinically impactful advancement in incretin-based metabolic research of the past decade.
For dosing, reconstitution, and protocol details, see our Tirzepatide Dosage Protocol Guide: GIP/GLP-1 Dual Agonist Reconstitution and Escalation for Research 2026.
Developed by Eli Lilly and Company, tirzepatide received FDA approval in May 2022 as Mounjaro for the treatment of type 2 diabetes mellitus, and subsequently as Zepbound in November 2023 specifically for chronic weight management. These landmark approvals were driven by an unprecedented body of clinical evidence spanning ten major phase 3 trials across the SURPASS and SURMOUNT programs.
For researchers, tirzepatide's unique pharmacological profile — combining two distinct incretin receptor pathways within a single molecular entity — has made it an exceptionally important compound for studying metabolic regulation, adipose tissue function, and the interplay between the GIP and GLP-1 hormonal axes.
---
Molecular Structure and Pharmacological Properties
Primary Sequence and Design
Tirzepatide's 39-amino-acid backbone was designed with balanced affinity at both GIP and GLP-1 receptors. Unlike selective GLP-1 agonists such as semaglutide or liraglutide, tirzepatide was engineered using the native GIP sequence as a scaffold, with specific modifications to introduce GLP-1 receptor binding capability.
Key structural features include:
- •Aib (alpha-aminoisobutyric acid) substitution at position 2: Prevents rapid DPP-4 cleavage, significantly extending circulating half-life
- •C20 fatty diacid moiety conjugated via a gamma-glutamic acid linker: Enables high-affinity albumin binding, dramatically reducing renal clearance
- •Once-weekly dosing feasibility: The extended half-life (~5 days) makes weekly subcutaneous administration practical for research protocols
- •Balanced receptor affinity: EC50 of ~2.7 nM at GIP receptor and ~6.3 nM at GLP-1 receptor (approximately native affinity at GIP, reduced affinity at GLP-1)
The reduced GLP-1 receptor affinity relative to native GLP-1 was intentional — researchers hypothesized that the synergistic combination of GIP and GLP-1 pathways would outperform maximally stimulating either alone.
Pharmacokinetic Profile
| Parameter | Value |
|---|---|
| Molecular weight | 4,813.45 Da |
| Half-life | ~5.0 days |
| Peak plasma concentration (Tmax) | 8–72 hours post-injection |
| Absolute bioavailability | ~80% (subcutaneous) |
| Primary elimination | Proteolytic degradation |
| Protein binding | >99% (albumin) |
| Steady state | Achieved at ~4 weeks with weekly dosing |
---
Mechanism of Action: Dual GIP/GLP-1 Receptor Agonism
The GLP-1 Receptor Pathway
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the distal intestine in response to nutrient ingestion. When tirzepatide activates GLP-1 receptors, the following physiological cascades occur:
Pancreatic effects:
- •Glucose-dependent stimulation of insulin secretion from beta cells (via cAMP/PKA signaling)
- •Suppression of glucagon release from alpha cells, reducing hepatic glucose output
- •Inhibition of beta-cell apoptosis and potential promotion of beta-cell proliferation (observed in preclinical models)
Gastric and intestinal effects:
- •Delayed gastric emptying, slowing the rate of nutrient absorption and blunting postprandial glucose excursions
- •Reduced intestinal motility contributing to early satiety
Central nervous system effects:
- •GLP-1 receptors in the hypothalamus, brainstem area postrema, and nucleus tractus solitarius modulate appetite signals
- •Reduced orexigenic drive; increased satiety signaling via afferent vagal pathways
- •Potential reward pathway modulation reducing food-seeking behavior
The GIP Receptor Pathway
Glucose-dependent insulinotropic polypeptide (GIP) is the other primary incretin hormone, secreted by K-cells in the proximal small intestine. Its role in metabolic regulation remained underappreciated for decades, but tirzepatide research has dramatically elevated understanding of GIP's physiological importance.
GIP receptor activation by tirzepatide mediates:
Pancreatic effects:
- •Insulin secretion augmentation (glucose-dependent, complementary to GLP-1 pathway)
- •Reduced glucotoxicity on beta cells via anti-apoptotic signaling
Adipose tissue effects:
- •Enhanced triglyceride clearance and uptake into adipocytes
- •Promotion of lipid storage under euglycemic conditions (paradoxically beneficial for redistributing ectopic fat)
- •Potential improvement in adipose tissue insulin sensitivity
- •Research in GIP receptor knockout models suggests GIP signaling is crucial for normal fat deposition patterns
Bone metabolism:
- •GIP receptors expressed in osteoblasts; activation may increase bone formation markers
- •Preliminary data suggest GIP agonism may improve bone mineral density (BMD)
Central effects:
- •GIP receptors present in hypothalamus and other CNS regions
- •Evidence from animal models shows GIP receptor activation in the CNS contributes to reduced food intake and body weight independent of GLP-1 signaling
Synergistic Dual-Receptor Mechanism
The key insight driving tirzepatide's development was that GIP and GLP-1 receptor pathways are synergistic rather than redundant. Several mechanisms underlie this synergy:
1. Different intracellular signaling kinetics: GIP and GLP-1 activate different temporal patterns of cAMP production in beta cells, leading to more sustained insulin secretion than either alone
2. Complementary CNS circuits: The brain regions mediating GIP's anorexigenic effects are distinct from those mediating GLP-1 effects, creating additive appetite suppression
3. GIP reverses GLP-1 nausea: Paradoxically, GIP receptor activation appears to reduce the nausea and emesis commonly associated with GLP-1 agonism, potentially explaining tirzepatide's superior tolerability despite its greater efficacy
4. Adipose tissue restructuring: GIP's role in adipocyte function, combined with GLP-1's effect on energy expenditure, leads to more comprehensive changes in body composition than GLP-1 agonism alone
---
Clinical Trial Evidence: The SURPASS Program
The SURPASS program (SURPASS 1 through 5) evaluated tirzepatide for glycemic control in type 2 diabetes, generating robust comparative data against placebo, semaglutide, and other reference compounds.
SURPASS-1: Monotherapy in T2DM
Design: 40-week randomized, placebo-controlled phase 3 trial in drug-naïve T2DM patients (N=478)
Key Results (tirzepatide 5mg / 10mg / 15mg vs placebo):
- •HbA1c reduction: −1.87% / −1.89% / −2.07% vs +0.04% (placebo)
- •Body weight reduction: −7.0 kg / −7.8 kg / −9.5 kg vs −0.7 kg (placebo)
- •Proportion achieving HbA1c <7%: 87% / 89% / 92% vs 20% (placebo)
- •Proportion achieving HbA1c ≤6.5%: 66% / 71% / 80% vs 11% (placebo)
Reference: Rosenstock et al., Lancet 2021 (SURPASS-1)
SURPASS-2: Tirzepatide vs Semaglutide 1mg
Design: 40-week open-label phase 3 trial comparing tirzepatide (5/10/15mg) to semaglutide 1mg in T2DM on metformin (N=1,879) — the pivotal head-to-head trial
Key Results:
| Endpoint | Tirzepatide 5mg | Tirzepatide 10mg | Tirzepatide 15mg | Semaglutide 1mg |
|---|---|---|---|---|
| HbA1c reduction | −1.86% | −2.09% | −2.37% | −1.86% |
| Weight reduction | −7.6 kg | −9.3 kg | −11.2 kg | −5.7 kg |
| HbA1c <7% | 82% | 87% | 92% | 79% |
| HbA1c ≤5.7% | 27% | 41% | 46% | 19% |
Critical finding: All three tirzepatide doses achieved superior weight loss vs semaglutide 1mg. The 15mg dose reduced weight by 11.2 kg vs 5.7 kg for semaglutide — nearly double the reduction. For complete comparison data, see our Semaglutide vs Tirzepatide Research Comparison.
Reference: Frías et al., New England Journal of Medicine 2021 (SURPASS-2)
SURPASS-3: Tirzepatide vs Insulin Degludec
Design: 52-week open-label phase 3 trial vs basal insulin in T2DM on metformin ± SGLT2 inhibitor (N=1,444)
Key Results (tirzepatide 5/10/15mg vs degludec):
- •HbA1c reduction: −1.93% / −2.20% / −2.37% vs −1.34%
- •Weight change: −7.5 kg / −10.7 kg / −12.9 kg vs +2.3 kg
- •Tirzepatide patients lost weight while insulin patients gained weight
- •Hypoglycemia incidence: Tirzepatide 10–15% vs insulin 22%
Reference: Ludvik et al., Lancet 2021 (SURPASS-3)
SURPASS-4: High Cardiovascular Risk Population
Design: 104-week randomized trial vs insulin glargine in T2DM with elevated CV risk (N=2,002) — longest SURPASS trial
Key Results (tirzepatide pooled):
- •HbA1c reduction: superior across all doses vs glargine
- •Weight reduction: −8.3 to −13.0 kg vs +1.0 kg (glargine)
- •eGFR: smaller decline with tirzepatide vs glargine over 104 weeks
- •Sustained glycemic and weight benefits through 2 years
Reference: Del Prato et al., Lancet 2021 (SURPASS-4)
SURPASS-5: Add-On to Basal Insulin
Design: 40-week placebo-controlled trial adding tirzepatide or placebo to insulin glargine in T2DM (N=475)
Key Results (tirzepatide 5/10/15mg vs placebo, added to glargine):
- •HbA1c reduction: −2.11% / −2.40% / −2.34% vs −0.86%
- •Weight change: −6.2 kg / −8.2 kg / −10.9 kg vs +1.6 kg (placebo gained weight)
- •Despite adding to insulin (typically associated with weight gain), all tirzepatide groups lost significant weight
Reference: Dahl et al., Diabetes Care 2022 (SURPASS-5)
---
Clinical Trial Evidence: The SURMOUNT Program
The SURMOUNT program evaluated tirzepatide specifically for chronic weight management in individuals with obesity or overweight, regardless of T2DM status.
SURMOUNT-1: Landmark Obesity Trial
Design: 72-week randomized, double-blind, placebo-controlled phase 3 trial in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with ≥1 weight-related comorbidity) without T2DM (N=2,539)
This is the pivotal trial demonstrating tirzepatide's unprecedented efficacy for weight reduction.
Primary Results (tirzepatide 5mg / 10mg / 15mg vs placebo):
| Endpoint | 5mg | 10mg | 15mg | Placebo |
|---|---|---|---|---|
| Mean body weight change | −15.0% | −19.5% | −20.9% | −3.1% |
| Mean kg lost | −15.2 kg | −19.9 kg | −22.5 kg | −3.2 kg |
| ≥5% weight loss | 85% | 89% | 91% | 35% |
| ≥10% weight loss | 69% | 79% | 83% | 15% |
| ≥15% weight loss | 50% | 67% | 69% | 8% |
| ≥20% weight loss | 30% | 50% | 57% | 3% |
Historical context: The 20.9% weight reduction at 15mg exceeded results seen with any previous single pharmacological compound in phase 3 trials. For context, bariatric surgery (RYGB) typically produces 25–35% weight loss.
Secondary endpoints: Waist circumference, blood pressure, fasting lipids, physical functioning (SF-36), and cardiometabolic markers all improved significantly vs placebo.
Reference: Jastreboff et al., New England Journal of Medicine 2022 (SURMOUNT-1)
SURMOUNT-2: Obesity with T2DM
Design: 72-week randomized trial in adults with T2DM and obesity/overweight (N=938)
Key Results (tirzepatide 10mg / 15mg vs placebo):
- •Body weight reduction: −13.4% / −15.7% vs −3.3%
- •HbA1c reduction: −2.1% / −2.4% vs −0.5%
- •Proportion achieving T2DM remission (HbA1c <6.5% without glucose-lowering medications): ~31% / ~40% vs 2%
Reference: Garvey et al., Lancet 2023 (SURMOUNT-2)
SURMOUNT-3: After Lifestyle Intervention
Design: 72-week trial examining tirzepatide after a 12-week lifestyle intervention run-in period (N=806)
Key Results (tirzepatide 15mg vs placebo, from lifestyle run-in baseline):
- •Total weight loss from pre-run-in: −26.0% (tirzepatide) vs −12.3% (placebo + lifestyle only)
- •Demonstrates additive effect of tirzepatide on top of behavioral intervention
Reference: Wadden et al., Nature Medicine 2023 (SURMOUNT-3)
SURMOUNT-4: Weight Maintenance After Tirzepatide
Design: Lead-in period of tirzepatide 10/15mg (36 weeks) followed by randomization to continued tirzepatide or switched to placebo (52 weeks) (N=670)
Key Results:
- •Those who continued tirzepatide: additional −5.5% weight reduction over maintenance period
- •Those switched to placebo: +14.8% weight regain
- •Underscores the chronic nature of obesity — pharmacotherapy discontinuation leads to weight rebound
Reference: Aronne et al., JAMA 2024 (SURMOUNT-4)
SURMOUNT-MMO: Cardiovascular Outcomes
A dedicated cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing with primary completion anticipated in 2025–2026, evaluating tirzepatide's impact on major adverse cardiovascular events (MACE) in individuals with obesity but without T2DM. Preliminary cardiovascular marker data from SURMOUNT-1/2 shows favorable trends in blood pressure, LDL-C, and inflammatory markers.
---
Cardiovascular and Metabolic Outcomes Research
Blood Pressure Effects
Across SURPASS and SURMOUNT trials, tirzepatide consistently reduced systolic blood pressure (SBP):
- •SURMOUNT-1: −4.2 to −6.2 mmHg SBP vs −0.4 mmHg (placebo) at 15mg
- •SURPASS-2: SBP reduction numerically greater with tirzepatide vs semaglutide
Lipid Profile Improvements
From pooled trial data:
- •LDL cholesterol: Modest reductions (5–10%)
- •Triglycerides: Significant reductions (20–30%) — particularly notable given GIP's role in lipid metabolism
- •HDL cholesterol: Small increases
- •Non-HDL cholesterol: Consistent reductions
Hepatic and Renal Effects
Hepatic:
- •Reduction in liver fat content measured by MRI-PDFF in metabolic dysfunction-associated steatotic liver disease (MASLD) studies
- •The SYNERGY-NASH trial evaluated tirzepatide specifically for NASH/MASLD; phase 2 results showed significant liver fat reduction and histological improvement
Renal:
- •SURPASS-4 (104 weeks) demonstrated smaller eGFR decline with tirzepatide vs insulin glargine
- •Phase 3 SURPASS-K trial in diabetic kidney disease ongoing
Inflammatory Markers
- •High-sensitivity CRP (hsCRP): Consistent reductions across trials, likely related to weight loss and adipose tissue remodeling
- •White blood cell count, uric acid, and other inflammatory markers improved
Sleep Apnea
SURMOUNT-OSA (phase 3): Tirzepatide significantly reduced apnea-hypopnea index (AHI) in adults with moderate-to-severe obstructive sleep apnea and obesity, leading to FDA approval for this indication in 2024.
---
Comparison to Semaglutide: Research Perspective
For researchers comparing tirzepatide and semaglutide, several key distinctions emerge from the clinical literature. See our comprehensive Semaglutide vs Tirzepatide Research Comparison for full analysis.
Weight Reduction Comparison
| Compound | Dose | Trial | Weight Change |
|---|---|---|---|
| Semaglutide | 2.4mg/week | STEP-1 | −14.9% |
| Tirzepatide | 15mg/week | SURMOUNT-1 | −20.9% |
| Semaglutide | 1mg/week | SURPASS-2 | −5.7 kg |
| Tirzepatide | 15mg/week | SURPASS-2 | −11.2 kg |
Mechanism-Based Differentiation
- •Receptor targets: Tirzepatide (dual GIP/GLP-1) vs semaglutide (selective GLP-1)
- •GI tolerability: Tirzepatide demonstrates comparable or better GI tolerability despite greater efficacy — attributed to the GIP component counteracting GLP-1-mediated nausea
- •Dose titration: Both require gradual dose escalation; tirzepatide uses a longer titration schedule (4-week intervals)
- •HbA1c reduction: Tirzepatide 15mg achieved −2.37% HbA1c vs semaglutide 1mg −1.86% in SURPASS-2
For a more detailed mechanistic comparison, consult the GLP-1 Receptor Agonists Complete Research Overview.
---
FDA Approval History
Mounjaro (T2DM Indication)
- •Approval date: May 13, 2022
- •Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- •Approved doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg (starting dose 2.5mg, titrated every 4 weeks)
- •Regulatory basis: SURPASS 1–5 program
- •Breakthrough therapy designation: Granted; Priority Review granted
Zepbound (Obesity/Weight Management Indication)
- •Approval date: November 8, 2023
- •Indication: Chronic weight management in adults with initial BMI ≥30 kg/m², or ≥27 kg/m² with ≥1 weight-related comorbidity, in conjunction with a reduced-calorie diet and increased physical activity
- •Regulatory basis: SURMOUNT 1–4 program
- •Clinical review: FDA recognized the unprecedented magnitude of weight loss (~22.5% maximum) as clinically meaningful
Sleep Apnea Indication (2024)
- •Approval date: June 2024
- •Indication: Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity
- •Regulatory basis: SURMOUNT-OSA phase 3 trials
---
Safety and Adverse Event Profile
Gastrointestinal Effects (Most Common)
From SURMOUNT-1 (15mg dose):
- •Nausea: 31.0% (tirzepatide) vs 10.5% (placebo)
- •Diarrhea: 22.1% vs 9.5%
- •Vomiting: 12.7% vs 2.3%
- •Constipation: 17.6% vs 6.1%
Timing: GI effects peak during dose escalation and typically diminish with time
Management: Slow titration (4-week intervals), dietary modifications
Discontinuation due to GI events: ~4.3% in SURMOUNT-1 at 15mg
Hypoglycemia
- •In non-diabetic subjects (SURMOUNT trials): hypoglycemia risk is very low (glucose-dependent mechanism)
- •In T2DM on insulin or sulfonylureas: risk increased; dose reduction of concomitant agents required
- •Severe hypoglycemia: rare in tirzepatide monotherapy
Cardiovascular
- •Heart rate increase: +1.4 to +3.9 bpm (dose-dependent) — class effect of GLP-1 RAs
- •Blood pressure: decreased (favorable)
Thyroid
- •Black box warning: Thyroid C-cell tumors in rodent models (class-wide GLP-1 RA concern)
- •Contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or MEN2
Contraindications
1. Personal or family history of medullary thyroid carcinoma
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
3. Hypersensitivity to tirzepatide or any excipients
---
Clinical Trial Dosing Design (Published Protocols)
Important disclaimer: The following dosing information is published from clinical trial protocols for educational and research reference purposes only.
Standard Phase 3 Trial Escalation Schedule
| Weeks | Dose |
|---|---|
| 1–4 | 2.5 mg/week |
| 5–8 | 5 mg/week |
| 9–12 | 7.5 mg/week |
| 13–16 | 10 mg/week |
| 17–20 | 12.5 mg/week |
| 21+ | 15 mg/week (maximum) |
In the trial protocols, administration was once-weekly subcutaneous injection with site rotation — a design detail relevant to replicating pharmacokinetic conditions in preclinical models.
Research Storage and Handling
| Specification | Detail |
|---|---|
| Molecular weight | 4,813.45 Da |
| Molecular formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| CAS Number | 2023788-19-2 |
| Appearance | White to off-white lyophilized powder |
| Reconstitution | Bacteriostatic water; gentle swirl, do not shake |
| Storage (lyophilized) | −20°C long-term; avoid repeated freeze-thaw cycles |
| Storage (reconstituted) | 2–8°C; use within 28 days |
| Purity standard | ≥98% by HPLC |
| Classification | Research Use Only (RUO) |
---
Emerging Research Areas
Retatrutide: The Next Generation
Where tirzepatide targets GIP + GLP-1 (dual), retatrutide adds glucagon receptor agonism to create a triple incretin agonist. Phase 2 data (Jastreboff et al., NEJM 2023) showed 24.2% weight loss over 48 weeks at the highest dose. Tirzepatide remains the benchmark against which next-generation compounds are evaluated.
MASLD/NASH Applications
Tirzepatide's combined effects on body weight, hepatic fat, and metabolic syndrome components make it a promising candidate for metabolic dysfunction-associated steatohepatitis (MASH). The SYNERGY-NASH trial (phase 3) is investigating tirzepatide as a treatment for MASH with fibrosis.
Heart Failure
The SUMMIT trial demonstrated significant improvements in exercise capacity (6-minute walk distance) and quality of life in heart failure with preserved ejection fraction (HFpEF) and obesity.
Muscle Preservation
A concern with all GLP-1 RA therapies is preservation of lean muscle mass. Preliminary data suggest tirzepatide's weight loss composition (~25–30% lean mass loss) is similar to dietary restriction; research on concurrent exercise protocols is active.
---
Supplier Sourcing for Research
For researchers sourcing tirzepatide, quality verification is paramount given the complexity of the molecule.
Analytical verification:
- •HPLC purity: Minimum 98%, ideally ≥99% by reverse-phase HPLC
- •Mass spectrometry: Molecular weight confirmation within 1 Da of theoretical (4,813.45 Da)
- •Endotoxin testing: LAL testing for research-grade material
- •Sterility: For injectable research preparations, documentation required
Compare verified tirzepatide suppliers on Peptides.SO for current pricing, purity ratings, and researcher reviews.
---
Tools for Researchers
- •Peptide Dose Calculator: Calculate research volumes based on peptide concentration and target doses
- •Dose Planner: Visualize dosing timelines and vial depletion for research planning
- •GLP-1 Receptor Agonists Overview: Comprehensive comparison of all major GLP-1/GIP agonists
- •Semaglutide vs Tirzepatide Comparison: Head-to-head mechanistic and clinical data comparison
- •Best Research Peptides for Weight Loss 2026: Current state of weight management peptide research
---
Key Research References
1. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205–216. [SURMOUNT-1] PMID: 35658024
2. Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503–515. [SURPASS-2] PMID: 34170647
3. Rosenstock J, et al. "Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes." Lancet. 2021;398(10295):143–155. [SURPASS-1] PMID: 34186022
4. Ludvik B, et al. "Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec." Lancet. 2021;398(10300):583–598. [SURPASS-3] PMID: 34370970
5. Del Prato S, et al. "Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk." Lancet. 2021;398(10313):1811–1824. [SURPASS-4] PMID: 34672967
6. Garvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes." Lancet. 2023;402(10401):487–499. [SURMOUNT-2] PMID: 37385275
7. Aronne LJ, et al. "Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity." JAMA. 2024;331(1):38–48. [SURMOUNT-4] PMID: 38078870
---
---
Tirzepatide Pricing & Supplier Review (September 2026)
Tirzepatide commands a premium over semaglutide in the research peptide market, reflecting its more complex dual-agonist synthesis and higher base cost. Here is what researchers should expect from current market pricing.
Tirzepatide Price Comparison (2026)
Based on our live database of 20+ research peptide vendors, here is a comprehensive 2026 tirzepatide price comparison (sourced from Peptides.SO listings, verified September 2026):
| Vendor | Price | Quantity | Price/mg |
|---|---|---|---|
| Royal Peptides | $50.00 | 1 mg | $50/mg |
| Polaris Peptides | $55.00 | 1 mg | $55/mg |
| HK Peptides Worldwide | $56.00 | 5 mg | $11.20/mg |
| Planet Peptide | $70.00 | 10 mg | $7/mg |
| HK Peptides Worldwide | $82.00 | 10 mg | $8.20/mg |
| Manifest Peptides | $89.99 | 1 mg | $89.99/mg |
| HK Peptides Worldwide | $102.00 | 15 mg | $6.80/mg |
| NUPEPS Peptides | $110.00 | 10 mg | $11/mg |
| Top Peptides | $110.99 | 5 mg | $22.20/mg |
| HK Peptides Worldwide | $117.00 | 20 mg | $5.85/mg |
| NuRev Peptides | $119.99 | 10 mg | $12/mg |
| Planet Peptide | $125.00 | 30 mg | $4.17/mg |
| NUPEPS Peptides | $150.00 | 30 mg | $5/mg |
| HK Peptides Worldwide | $165.00 | 30 mg | $5.50/mg |
| Planet Peptide | $180.00 | 60 mg | $3/mg |
| HK Peptides Worldwide | $246.00 | 60 mg | $4.10/mg |
> Data sourced from Peptides.SO live listings (verified September 2026: 20 active suppliers, 56 in-stock listings). Research Use Only (RUO) — not for human use.
Market Summary (20 active suppliers, 56 in-stock listings, September 2026):
- •Small quantity (1 mg): $50–$130/mg
- •Mid-quantity (5–10 mg): $7–$22/mg
- •Bulk (20–60 mg): $3–$6/mg
- •Most competitive bulk rate: ~$3/mg (Planet Peptide, 60mg format)
→ See live real-time pricing with all vendors at our Tirzepatide Price Comparison page.
Tirzepatide vs Semaglutide: Research Cost Comparison
| Compound | Price Range | Avg/vial | Half-life | Max Weight Reduction |
|---|---|---|---|---|
| Semaglutide | $30–$540 | ~$172 | 7 days | ~15% (STEP 1) |
| Tirzepatide | $50–$300+ | ~$289 | 5 days | ~20.9% (SURMOUNT-1) |
Tirzepatide typically costs 30–60% more per vial than semaglutide. For research budgets comparing compound efficacy-to-cost ratios, this premium may be justified given superior SURMOUNT-1 outcomes. Both compounds are available in comparable supply from domestic US vendors.
Reconstitution Reference
For a standard tirzepatide research vial (5mg):
- •Add 1.0 mL bacteriostatic water → 5mg/mL
- •Add 2.5 mL bacteriostatic water → 2mg/mL
- •Store reconstituted: 2–8°C, use within 28 days
- •Vials are sensitive to light — store in amber vials or wrapped in foil
Key Quality Indicators for Tirzepatide Sourcing
1. Sequence verification — Tirzepatide is a 39-amino acid synthetic peptide with specific GIP and GLP-1 pharmacophore domains. Request mass spectrometry data showing correct molecular weight (MW: ~4,813 Da)
2. Purity minimum — Research-grade tirzepatide should show ≥98% purity by HPLC
3. Endotoxin testing — For injectable research applications, bacterial endotoxin testing (BET/LAL) certification is advisable
4. Lyophilized powder preferred — Avoid pre-constituted liquid tirzepatide from unknown vendors
For live pricing across all tirzepatide vendors, visit our Tirzepatide Price Comparison page. To compare directly with semaglutide pricing and efficacy data, see our Semaglutide vs Tirzepatide Research Comparison. Use the Peptide Dose Calculator for protocol planning.
---
---
Further Reading:
- •Semaglutide vs Tirzepatide: Price, Efficacy, and Supplier Comparison 2026
- •GIP (Glucose-Dependent Insulinotropic Polypeptide): The Forgotten Incretin Driving the Dual-Agonist Revolution
- •Retatrutide (LY3437943): Triple Hormone Receptor Agonist — Complete Research Profile
- •Semaglutide Research Guide 2026: Mechanism, Dosing, Sources, and Pricing
- •Reconstitution Calculator
- •Peptide Stack Builder
---
Frequently Asked Questions
Is tirzepatide FDA-approved?
Yes — tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), based on the SURPASS and SURMOUNT clinical trial programs (SURPASS-1, Lancet, PMID 34186022).
How is tirzepatide mechanistically different from semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor co-agonist, while semaglutide acts only at the GLP-1 receptor. This dual-agonism is associated with a distinct, imbalanced/biased signaling profile relative to native GIP and GLP-1 (JCI Insight, PMID 32730231).
What does the meta-analysis evidence show for tirzepatide's efficacy?
A systematic review and meta-analysis across the SURPASS program found tirzepatide produced superior glycemic control and body-weight reduction compared to other GLP-1-based therapies and insulin comparators in type 2 diabetes research (Diabetologia, PMID 35579691).
Why does tirzepatide cost more than semaglutide in the research peptide market?
Tirzepatide is a larger, more structurally complex 39-amino-acid dual-agonist peptide, which increases synthesis cost relative to semaglutide's 31-residue single-agonist structure — reflected in the ~30-60% per-vial premium documented in the pricing table above.
What research is emerging beyond metabolic indications?
Current literature reviews highlight expanding investigation of GIP/GLP-1 dual-agonist mechanisms across cardiovascular and broader metabolic-disease research contexts (Frontiers in Endocrinology, PMID 39114288).
Where can I compare live tirzepatide pricing across suppliers?
See the Tirzepatide Price Comparison page for continuously updated vendor pricing, or the Semaglutide vs Tirzepatide comparison for a side-by-side cost/efficacy breakdown.
---
Research Disclaimer
The content on this page is intended for educational and informational purposes for the scientific research community only. Tirzepatide (Mounjaro®, Zepbound®) is a prescription medication approved by the FDA for specific indications; it is not approved for self-administration or use outside of medical supervision.
All clinical data referenced is derived from published, peer-reviewed research. Peptides.SO does not provide medical advice, diagnose conditions, or recommend treatments. Researchers and consumers should consult qualified healthcare professionals for all medical decisions.
Peptide compounds sold through verified suppliers on Peptides.SO are sold for laboratory research use only (RUO) and are not intended for human consumption, therapeutic use, or veterinary administration.